Gabelli Funds' Q1 2026 Portfolio Adjustments: A Deep Dive
Finance

Gabelli Funds' Q1 2026 Portfolio Adjustments: A Deep Dive

authorBy Nouriel Roubini
DateMay 19, 2026
Read time3 min

Gabelli Funds' first-quarter 2026 13F portfolio maintained a stable value of $14.81 billion, featuring over 1,200 positions. Notably, 31 core holdings each represented more than 0.5% of the total assets, underscoring a diversified yet focused investment strategy. The top five holdings—Newmont, Nvidia, National Fuel Gas, Alphabet, and Ametek—collectively accounted for approximately 7.5% of the portfolio, reflecting a clear long-term value orientation. The firm strategically reduced its exposure to several long-standing positions, including Newmont, Alphabet, Ametek, and Microsoft, indicating a proactive approach to crystallize profits from successful investments. Conversely, minor increases were observed in holdings like Nvidia, Eli Lilly, and Lennar Holdings. These broad reductions across the portfolio signal a disciplined rebalancing effort, particularly in an environment characterized by elevated market valuations.

Gabelli Funds Navigates Q1 2026 with Strategic Portfolio Rebalancing

In the first quarter of 2026, Gabelli Funds, a prominent investment management firm, executed a series of calculated adjustments to its 13F portfolio, maintaining a robust total value of $14.81 billion. This quarter's activity, meticulously detailed in their regulatory 13F filing on May 14, 2026, reveals a thoughtful strategy focused on long-term value and disciplined profit-taking amidst shifting market dynamics. The portfolio’s expansive nature is highlighted by its more than 1,200 positions, with a concentrated core of 31 holdings each exceeding 0.5% of the total managed assets. These significant positions underscore the firm's conviction in specific companies and sectors. The leading five holdings—Newmont, Nvidia, National Fuel Gas, Alphabet, and Ametek—collectively represent approximately 7.5% of the entire portfolio. This concentration in established entities suggests a preference for stability and proven performance. A notable trend observed during this period was the strategic reduction in several legacy positions. Gabelli Funds trimmed its stakes in Newmont, Alphabet, Ametek, and Microsoft, among others. This move indicates a deliberate effort to harvest profits from investments that have matured or reached peak valuations. Such reductions free up capital for redeployment into new opportunities or to strengthen existing positions with higher growth potential. Conversely, the firm made modest increases in a few selected holdings, including Nvidia, Eli Lilly, and Lennar Holdings. These targeted additions suggest a selective approach to growth, focusing on companies that are expected to outperform in the coming periods. Overall, the broad-based reductions across many positions, coupled with targeted increases, reflect a disciplined rebalancing act. Gabelli Funds appears to be cautiously navigating the current market landscape, characterized by potentially elevated valuations, by locking in gains and selectively investing in future growth drivers. This methodical approach aims to optimize the portfolio for sustained long-term returns while mitigating risks associated with market fluctuations.

This quarter's portfolio adjustments by Gabelli Funds highlight the critical importance of active management and strategic rebalancing in investment success. The firm's actions demonstrate a commitment to realizing profits from mature positions while selectively bolstering investments in promising growth areas. For individual investors, this serves as a valuable lesson: regularly reviewing and adjusting one's portfolio based on market conditions and company performance is essential. It's not just about holding onto winners indefinitely, but also about knowing when to trim, take profits, and reallocate capital to maintain a balanced and resilient investment strategy. Furthermore, the focus on long-term value, even in a dynamic market, reinforces the idea that patience and thorough research are cornerstones of effective investing.

More Articles
Finance
Franklin New York Tax-Free Income Fund's Q1 2026 Performance and Outlook
The Franklin New York Tax-Free Income Fund outperformed its benchmark in Q1 2026. The Federal Reserve anticipates focusing on core inflation despite potential oil supply shocks. The fund's yield curve positioning, particularly an overweight in long-term muni bonds, negatively impacted performance. However, strategic rating allocations, favoring unrated and BBB-rated bonds, boosted returns. Management highlights the continued attractiveness of municipal bond valuations, especially considering tax benefits.
By Robert KiyosakiMay 19, 2026
Finance
Q1 2026 US Retail Preview: Broadline Retail Powers Earnings Growth As Household Durables Weaken
The LSEG U.S. Retail and Restaurant Q1 earnings index is projected to exhibit a 25.2% increase compared to the previous year. Within this sector, broadline retail is anticipated to lead with a substantial 73.1% surge in earnings growth. Conversely, the Household Durables sector faces a projected decline of -25.6%, indicating a significant weakening in its profit outlook.
By Strive MasiyiwaMay 19, 2026
Finance
MSC Income Fund: An Attractive Investment Opportunity with Strong NAV Growth and Dividend Coverage
MSC Income Fund (MSIF) has received an upgrade to 'Buy' due to its compelling 24% discount to Net Asset Value (NAV), improving dividend coverage, and consistent NAV growth. The fund's diversified, primarily first-lien, floating-rate portfolio contributes to an attractive 10.9% yield, with potential for additional distributions given strong cash flows. Despite sector challenges like elevated interest rates, MSIF maintains a robust net investment activity and low portfolio concentration.
By Robert KiyosakiMay 19, 2026
Finance
Abrdn Healthcare Opportunities Fund: Q1 2026 Performance Overview
The Abrdn Healthcare Opportunities Fund experienced a decline in its equity portion during the first quarter of 2026, underperforming its benchmark. Key detractors included Abbott Laboratories due to diagnostic and nutrition segment weakness, while BioCryst Pharmaceuticals positively contributed with strong rare disease franchise growth. The fund maintained a balanced approach, adding small- and mid-cap biotech and specialty pharmaceutical companies, alongside risk management strategies like covered call writing and fixed income allocations.
By Lisa JingMay 19, 2026
Finance
Apple: Current Valuation Limits Upside Potential
Despite Apple's strong Q2 results, robust Q3 guidance, and a significant buyback program, its elevated forward P/E of 34.10, near multi-year highs, suggests that much of the positive news is already priced into the stock. While long-term investors may consider holding, new buyers face limited near-term upside due to potential risks like China iPhone price cuts and memory cost headwinds, leading to a downgraded recommendation.
By Michele FerreroMay 19, 2026